This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire plc
Shire plc, a leading global biotechnology company headquartered in Ireland (IE), focuses on developing innovative therapies for rare diseases and complex conditions. Founded in 1986, Shire has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in areas such as neuroscience, immunology, and genetic disorders, Shire is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic conditions. The company has achieved significant milestones, including numerous FDA approvals and a robust pipeline of therapies that address unmet medical needs. With a commitment to improving patient outcomes, Shire plc has solidified its position as a market leader in the biotechnology sector, recognised for its dedication to innovation and excellence in healthcare.
DitchCarbon Score
How does Shire plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire plc's score of 68 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire plc, headquartered in Ireland (IE), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and emissions reporting. As part of its climate strategy, Shire plc inherits reduction initiatives and targets from Takeda Pharmaceutical Company Limited. However, specific reduction targets or achievements for Shire plc itself are not detailed in the available data. The company is involved in broader industry initiatives, including those related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the parent company level. While Shire plc has not disclosed its own emissions figures, it is committed to aligning with the climate goals set forth by Takeda, which may include significant reduction targets and sustainability initiatives. The lack of specific emissions data suggests that Shire plc is still in the process of establishing its own reporting framework or may rely on aggregated data from its parent company. In summary, Shire plc's climate commitments are currently shaped by its relationship with Takeda Pharmaceutical Company Limited, with no specific emissions data or reduction targets reported at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
